Boost for gliptins in PBS pecking order
In a shake-up to the management of type 2 diabetes, doctors can now skip sulfonylureas and add any gliptin straight to metformin, the Department of Health says.
From Tuesday, the PBS was due to subsidise all five gliptins (DPP-4 inhibitors) in combination with either metformin or a sulfonylurea for patients with an HbA1c above 7% (53mmol/mol).
The easing of the restrictions brings consistency across the class.
Alogliptin (Nesina) was the first to gain this expanded PBS listing in December; now linagliptin (Trajenta), saxagliptin (Onglyza),